Sign In

Lukasz Jarzyna

Commercial Leader Passionate About Biopharmaceuticals & Rare Diseases

Lukasz Jarzyna is the Vice President and Head of Bone, Metabolism, and Rare Cancers Global Marketing at Alexion Pharmaceuticals, Inc. He has a diverse background that combines a passion for healthcare and economics. Originally from Poland, Jarzyna aspired to be a doctor and work on HIV cures during his teenage years, influenced by his parents' involvement with an AIDS foundation. However, he ultimately pursued a degree in economics and began his career as a tax and accounting consultant in Vienna, Austria, where he started working with biopharma clients, including Amgen.

Jarzyna joined Amgen in Vienna, focusing on business planning and analysis, before moving to Zug, Switzerland. In 2015, he transitioned to Alexion Pharmaceuticals, initially working in strategic planning. He later became the head of global value, access, and pricing, where he has made significant contributions to the company's approach to drug pricing and access, particularly in the realm of rare diseases. His work has included developing sustainable pricing strategies and innovative access agreements to improve patient access to treatments like Ultomiris (ravulizumab) for paroxysmal nocturnal hemoglobinuria (PNH) .12

Jarzyna's commitment to addressing drug access delays is driven by his personal experiences and a strong sense of responsibility to improve the healthcare landscape, especially for patients with rare diseases. He emphasizes the importance of collaboration with stakeholders to expedite access to medicines, aiming to reduce the average time patients wait for treatment after regulatory approval .1

Highlights

Apr 2 · linkedin

80% of the 10,000 known rare diseases are genetic, giving rise to a relatively new area of medicine: gene therapy, a treatment approach that can be curative for genetic disorders. These one-time or long-term treatments have the potential to transform the lives of rare disease patients and their families and reduce the burden on our healthcare systems, particularly in the hospital setting. But, like many medicines, gene therapies can only be transformative if the patients who need them have access to them in the first place.

Last week, at the Reuters Pharma USA conference, I had the opportunity to discuss some of the current challenges of bringing these therapies to market: How do you establish value for a long-term treatment or cure? How do you navigate system affordability and market access, especially for smaller insurers? And how can you help facilitate patient and physician adoption of this new class of treatment?

The simple answer is: collaboration. In the US, there are a number of approaches under consideration to address these challenges, such as designing innovative payment mechanisms and testing different payment models and reimbursement systems, but it will take collaboration across the entire healthcare ecosystem to find a sustainable solution.

It’s still early days for gene therapy and we have a lot of work ahead of us to ensure patients can get access to these transformative treatments, but I am really encouraged by the progress and momentum I am seeing across the industry and what it means for #raredisease patients, their families, and our healthcare system.

Thank you Reuters Events Pharma for the opportunity and for putting a spotlight on #genetherapy last week at #REpharmaUSA

Alexion Pharmaceuticals, Inc., Michaela Menard, Shijia Wang

Jan 22 · linkedin

Excited to share that I will be joining the speaker faculty at Pharma USA 2024. Learn more and join me here: https://bit.ly/4b2jqwO   I look forward to joining the panel on Cell and Gene Therapy track and sharing my thoughts on the topic of linking long term durability consideration back to pricing strategy to broaden market access. Don’t miss out! #REpharmaUSA

Alexion Pharmaceuticals, Inc. Michaela Menard

Related Questions

What inspired Lukasz Jarzyna to transition from economics to the pharmaceutical industry?
How has Lukasz Jarzyna's work impacted access to rare disease treatments globally?
What are some of the challenges Lukasz Jarzyna faces in his role at Alexion Pharmaceuticals?
How does Lukasz Jarzyna's background in economics influence his approach to drug pricing?
What initiatives has Lukasz Jarzyna implemented to reduce drug-access delays?
Lukasz Jarzyna
Lukasz Jarzyna, photo 1
Lukasz Jarzyna, photo 2
Add to my network

Location

Boston, Massachusetts, United States